Abstract
These recommendations describe the minimum standard criteria for genetic counseling and testing of individuals and families with fragile X syndrome, as well as carriers and potential carriers of a fragile X mutation. The original guidelines (published in 2000) have been revised, replacing a stratified pre- and full mutation model of fragile X syndrome with one based on a continuum of gene effects across the full spectrum of FMR1 CGG trinucleotide repeat expansion. This document reviews the molecular genetics of fragile X syndrome, clinical phenotype (including the spectrum of premature ovarian failure and fragile X-associated tremor-ataxia syndrome), indications for genetic testing and interpretation of results, risks of transmission, family planning options, psychosocial issues, and references for professional and patient resources. These recommendations are the opinions of a multicenter working group of genetic counselors with expertise in fragile X syndrome genetic counseling, and they are based on clinical experience, review of pertinent English language articles, and reports of expert committees. These recommendations should not be construed as dictating an exclusive course of management, nor does use of such recommendations guarantee a particular outcome. The professional judgment of a health care provider, familiar with the facts and circumstances of a specific case, will always supersede these recommendations.
Similar content being viewed by others
References
Allingham-Hawkins, D. J., Babul-Hirji, R., Chitayat, D., Holden, J. J., Yang, K. T., Lee, C., et al. (1999). Fragile X premutation is a significant risk factor for premature ovarian failure: The International Collaborative POF in Fragile X study—preliminary data. Am J Med Genet, 83, 322–325.
American College of Medical Genetics (1994). American College of Medical Genetics Policy Statement. Fragile X syndrome: diagnostic and carrier testing. Am J Med Genet, 53, 380–381.
American College of Medical Genetics/American Society of Human Genetics (ACMG/ASHG) (1995). Genetic testing in children and adolescents: Points to consider: Ethical legal and psychosocial implications of. Am J Hum Genet, 57, 1233–1241.
Anido, A., Carlson, L. M., Taft, L., & Sherman, S. L. (2005). Women’s attitudes toward testing for fragile X carrier status: A qualitative analysis. J Genet Couns, 14, 295–306.
Apessos, A., Abou-Sleiman, P., Harper, J., & Delhanty, J. (2001). Preimplantation genetic diagnosis of the fragile X syndrome by use of linked polymorphic markers. Prenat Diagn, 21, 504–511.
ASHG/ACMG (1995). Points to consider: Ethical, legal, and psychological implications of genetic testing in children and adolescents. Am J Hum Genet, 57, 1233–1241.
Ashley, A. E., & Sherman, S. L. (1995). Population dynamics of a meiotic/mitotic expansion model for the fragile X syndrome. Am J Hum Genet, 57, 1414–1425.
Aziz, M. (2003). Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet, 121B(1), 119–127.
Bailey, D. B. (2004). Newborn screening for fragile X syndrome. Ment Retard Dev Disabil Res Rev, 10, 3–10.
Baker, D. L., Schuette, J. L., & Uhlmann, W. R. (Eds.) (1998). A guide to genetic counseling. New York: Wiley-Liss.
Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Neuroscience, 27, 370–377.
Bell, M. V., Hirst, M. C., Nakahori, Y., Mackinnon, R. N., Roche, A., Flint, et al. (1991). Physical mapping across the fragile X: Hypermethylation and clinical expression of the fragile X syndrome. Cell, 64, 861–866.
Bennett, R. L., Hart, K. A., O’Rourke, E., Barranger, J. A., Johnson, J., MacDermot, K. D., et al. (2002). Fabry disease in genetic counseling practice: Recommendations of the National Society of Genetic Counselors. J Genet Couns, 11(2), 121–146.
Brown, W. T. (2002). The molecular biology of the fragile X mutation. In R. J. Hagerman & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment and research (3rd Ed., pp. 110–135). Baltimore: The Johns Hopkins University Press.
Brown, W. T., Houck, G. E., Ding, X., Zhong, N., Nolin, S., Glicksman, A., et al. (1996a). Reverse mutations in the fragile X syndrome. Am J Med Genet, 64, 287–292.
Brown, W. T., Houck, G. E., Jeziorowska, A., Jeziorowka, A., Levinson, F. N., Ding, X., et al. (1993). Rapid fragile X carrier screening and prenatal diagnosis using nonradioactive PCR test. JAMA, 270, 1569–1575.
Brown, W. T., Nolin, S., Houck, G. E., Ding, X., Glicksman, A., Li, S. Y., et al. (1996b). Prenatal diagnosis and carrier screening for fragile X by PCR. Am J Med Genet, 64(1), 191–195.
Cantu, J. M., Diaz-Gallardo, M. Y., Barros-Nunez, P., & Figuera, L. E. (1998). Heteroallelic monozygotic twins and triplets. Am J Med Genet, 77, 166–167 (letter to editor).
Chakravarti, A. (1992). Fragile X founder effect? Nat Genet, 1, 237.
Ciarleglio, L. J., Bennett, R. L., Williamson, J., Mandell, J. B., & Marks, J. H. (2003). Genetic counseling throughout the life cycle. J Clin Invest, 112, 1280–1286.
Conway, G., Hettiarachchi, S., Murray, A., & Jacabs, P. (1995). Fragile X premutations in familial premature ovarian failure. Lancet, 346, 309–310.
Crawford, D., Meadows, K., Newman, J., Taft, L., Pettay, D., Gold, L., et al. (1999). Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population. Am J Hum Genet, 64, 495–507.
Crawford, D., Meadows, K., Newman, J., Taft, L., Scott, E., Leslie, M., et al. (2002). Prevalence of the fragile X syndrome in African-Americans. Am J Med Genet, 110(3), 226–233.
Cronister, A., Hagerman, R. J., Wittenberger, M., & Amiri, K. (1991). Mental impairment in cytogenetically positive fragile X females. Am J Med Genet, 38, 503–504.
De Boulle, K., Verkerk, A. J. M. H., Reyniers, E., Vits, L., Dendrickx, J., Van Roy, B., et al. (1993). A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet, 3, 31–35.
de Graaff, E., Willemsen, R., Zhong, N., de Die-Smulders, C. E., Brown, W. T., Freling, G., et al. (1995). Instability of the CGG repeat and expression of the FMR1 protein in a male fragile X patient with a lung tumor. Am J Hum Genet, 3, 609–618.
De Vries, B. B. A., Van den Ouweland, A. M., Mohkamsing, S., Duivenvoorden, H. J., Mol, E. Gelsema, K., et al. (1997). Screening and diagnosis for the fragile X syndrome among the mentally retarded: An epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet, 61, 660–667.
De Vries, B. B. A., Wiegers, A. M., Smits, A. P. T., Mohkamsing, S., Duivenvoorde, J. H., Fryns, J. P., et al. (1996). Mental status of females with an FMR-1 gene full mutation. Am J Hum Genet, 58, 1025–1032.
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J. P., & Mandel, J. L. (1993). The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet, 4, 335–340.
Eichler, E. E., Holden, J., Popovich, B. W., Reiss, A. L., Snow, K., Thibodeau, S. N., et al. (1994). Length of uninterrupted CGG repeats determines instability in the FMR-1 gene. Nat Genet, 8, 88–94.
Erster, S. H., Brown, W. T., Goodewardena, P., Dobkin, S., Jenkins, E. C., Pergolizzi, R. G. (1992). Polymerase chain reaction analysis of fragile X mutations. Hum Genet, 90, 55–61.
Feng, Y., Shang, F., Lokey, L. K., Chastian, J. L., Lakkis, L., Eberhart, D., et al. (1995). Translational suppression by trinucleotide repeat expansion at FMR1. Science, 268, 731–734.
Finucane, B. (1996). Should all pregnant women be offered carrier testing for fragile X syndrome? Clin Obstet Gynecol, 39, 772–781.
Finucane, B. (1998a). Acculturation in women with mental retardation and its impact on genetic counseling. J Genet Couns, 7, 31–47.
Finucane, B. (1998b). Working with women who have mental retardation: A genetic counselor’s guide. Elwyn, PA: Elwyn.
Fisch, G. S., Snow, K., Thibodeau, S. N., Chalifaux, M., Holden, J. J. A., Nelson, D. L., et al. (1995). The fragile X premutation in carriers and its effect on mutation size in offspring. Am J Hum Genet, 56, 1147–1155.
Franke, P., Leboyer, M., Gansicke, M., Weiffenbach, O., Biancalana, V., et al. (1998). Genotype–phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res, 80(2), 113–127.
Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., et al. (1991). Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell, 67, 1047–1058.
Gedeon, A. K., Baker, E., Robinson, H., Partington, M. W., Gross, B., Manca, A., et al. (1992). Fragile X syndrome without CCG amplification has an FMR1 deletion. Nat Genet, 1, 341–344.
Gonzalez-del Angel, A., Vidal, S., Saldana, Y., del Castillo, V., Angel Alcantara, M., Macias, M., et al. (2000). Molecular diagnosis of the fragile X and FRAXE syndromes in patients with mental retardation of unknown cause in Mexico. Ann Genet, 43(1), 29–34.
Hagerman, P. J., & Hagerman, R. J. (2004). The fragile X premutation: A maturing perspective. Am J Hum Genet, 74, 805–816.
Hagerman, R. J. (2002). The physical and behavioral phenotype. In R. J. Hagerman & P. J. Hagerman (Eds.), Fragile X syndrome, diagnosis treatment, and research (3rd Ed., pp. 3–109). Baltimore: Johns Hopkins University Press.
Hagerman, R. J., Hull, C. E., Safanda, J. F., Carpenter, I., Staley, L. W., O’Connor, R. A., et al. (1994). High functioning fragile X males: Demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet, 51, 298–308.
Hagerman, R. J., Leavitt, B. R., Farzin, F., Jacquemont, S., Greco, C. M., Brunberg, J. A., et al. (2004). Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet, 64, 1051–1056.
Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., et al. (2001). Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology, 57, 127–130.
Hecimovic, S., Tarnik, I., Baric, I., Cakarun, Z., Pavelic, K. (2002). Screening for fragile X syndrome: Results from a school for mentally retarded children. Acta Paediatr, 91(5), 535–539.
Heitz, D., Rousseau, F., Devys, D., Saccone, S., Abderrahim, H., Le Paslier, D., et al. (1991). Isolation of sequences that span the fragile X and identification of a fragile X-related CpG island. Science, 251, 1236–1239.
Helderman-van den Enden, A. T. J. M., Maaswinkel-Mooij, P. D., Hoogendoorn, E., Willemsen, R., Maat-Kievit, J. A., Losekoot, M., et al. (1999). Monozygotic twin brothers with the fragile X syndrome: Different CGG repeats and different mental capacities. J Med Genet, 36, 253–357.
Hundscheid, R. D., Sistermans, E. A., Thomas, C. M. G., Braat, D. D. M., Straatman, H., & Kiemeney, L. A. L. M. (2000). Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations. Am J Hum Genet, 66, 413–418.
Hundscheid, R. D., Smits, A. P., Thomas, C. M., Kiemeney, L. A., & Braat, D. D. (2003). Female carriers of fragile X premutations have no increased risk for additional diseases other than premature ovarian failure. Am J Med Genet, 117A, 6–9.
Iida, T., Nakahor, Y., Tsutsumi, O., Taketinin, Y., & Nakagome, Y. (1994). The CPG island of the FMR-1 gene is methylated differently among embryonic tissues: Implication for prenatal diagnosis. Hum Reprod, 9, 1471–1473.
Jacquemont, S., Hagerman, R. J., Leehey, M. A., Hall, D. A., Levine, R. A., et al. (2004). Penetrance of the fragile X-associated tremor-ataxia syndrome in a premutation carrier population. JAMA, 291(4), 460–469.
Johnston, C., Eliez, S., Dyer-Friedman, J., Hessl, D., Glaser, B., et al. (2001). Neurobehavioral phenotype in carriers of the fragile X premutation. J Med Genet, 103(4), 314–319.
Kessler, S., Kessler, H., & Ward, P. (1984). Psychological aspects of genetic counseling. III. Management of guilt and shame. J Med Genet, 17, 673–697.
Keysor, C. S., & Mazzocco, M. M. (2002). A developmental approach to understanding fragile X syndrome in females. Microscopy Research and Technique, 57, 179–186.
Kielinen, M., Rantala, H., Timonen, E., Linna, S., & Moilanen, I. (2004). Associated medical disorders and disabilities in children with autistic disorder: A population-based study. Autism, 8(1), 49–60.
Kolehmainen, K. (1994). Population genetics of fragile X: A multiple allele model with variable risk of CGG repeat expansion. Am J Med Genet, 51, 428–435.
Kremer, E. J., Pritchard, M., Lynch, M., Yu, S., Holman, K., Baker, E., et al. (1991). Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science, 252, 1711–1714.
Kunst, C. B., & Warren, S. T. (1994). Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. Cell, 77, 853–861.
Lachiewicz, A. M., Spiridigliozzi, G. A., McConkie-Rosell, A., Burgess, D., & Tarleton, J. (1996). A fragile X male with a broad smear on Southern Blot of 100 to 500 CGG repeats and no methylation. Am J Med Genet, 64, 278–282.
Loesch, D., Petrovic, V., Francis, D., Oertel, R., & Slater, H. (1995). Reduction of GCC trinucleotide expansion from mother to offspring in seven fragile-X families. Clin Genet, 51(1), 1–6.
Lubs, H. A. (1969). A marker X chromosome. Am J Hum Genet, 21, 231–244.
Maddalena, A., Richards, C. S., McGinnis, M. J., Brothman, A., Desnick, R. J., Grier, R. E., et al. (2001). Technical standards and guidelines for fragile X: The first of a series of disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet Med, 3, 200–205.
Malter, H. E., Iber, J. C., Willemsen, R., de Graaff, E., Tarleto, J. C., Leisti, J., et al. (1997). Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet, 15, 165–169.
Marteau, T. M., Dundas, R., & Axworthy, D. (1997). Long-term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: The effects of test result and gender. Health Psychol, 16(1), 51–62.
Marymee, K., Dolan, C. R., Pagon, R. A., Bennett, R. L., Coe, S., & Fisher, N. L. (1998) Development of critical elements of genetic evaluation and genetic counseling for genetic professionals and perinatologists in Washington State. J Genet Couns, 7, 133–165.
McConkie-Rosell, A., & DeVellis, B. M. (2000). Threat to parental role: A possible mechanism of altered self-concept related to carrier knowledge. J Genet Couns, 9, 285–302.
McConkie-Rosell, A., Lachiewicz, A. M., Spiridigliozzi, G. A., Tarleton, J., Schoenwald, S. Phelan, M. C., et al. (1993). Evidence that methylation of the FMR-1 locus is responsible for variable phenotypic expression of the fragile X syndrome. Am J Hum Genet, 53, 800–809.
McConkie-Rosell, A., Robinson, H., Wake, S., Staley, L., Heller, K., & Cronister, A. (1995). The dissemination of genetic risk information to relatives in the fragile X syndrome: Guidelines for genetic counselors. Am J Med Genet, 59, 426–430.
McConkie-Rosell, A., & Spiridigliozzi, G. A. (2004). “Family matters”: A conceptual framework for genetic testing in children. J Genet Couns, 13, 9–29.
McConkie-Rosell, A., Spiridigliozzi, G. A., Dawson, D. V., Sullivan, J. A., & Lachiewicz, A. M. (2001). Longitudinal study of the carrier testing process for fragile X syndrome: Perceptions and coping. Am J Med Genet, 98, 37–45.
McConkie-Rosell, A., Spiridigliozzi, G. A., Iafolla, T., Tarleton, J., & Lachiewicz, A. M. (1997). Carrier testing in the fragile X syndrome: Attitudes and opinions of obligate carriers. Am J Med Genet, 68, 62–69.
McConkie-Rosell, A., Spiridigliozzi, G. A., Rounds, K., Dawson, D. V., Sullivan, J. A., Burgess, D., et al. (1999). Parental attitudes regarding carrier testing in children at risk for fragile X syndrome. Am J Med Genet, 82, 206–211.
McConkie-Rosell, A., Spiridigliozzi, G. A., Sullivan, J. A., Dawson, D. V., & Lachiewicz, A. M. (2000). Carrier testing in fragile X syndrome: Effect on self-concept. Am J Med Genet, 92, 336–342.
McConkie-Rosell, A., Spiridigliozzi, G. A., Sullivan, J. A., Dawson, D. V., & Lachiewicz, A. M. (2002). Carrier testing in fragile X syndrome: When to tell and test. Am J Med Genet, 110, 36–44.
McIntosh, N., Gane, L. W., McConkie-Rosell, A., & Bennett, R. L. (2000). Genetic counseling for fragile X syndrome: Recommendations of the National Society of Genetic Counselors. J Genet Couns, 9, 303–325.
Meadows, K. L., Pettay, D., Newman, J., Hersey, J., Ashley, A. E., & Sherman, S. L. (1996). Survey of the fragile X syndrome and the fragile X E syndrome in a special education needs population. Am J Med Genet, 64, 428–433.
Merenstein, S. A., Sobesky, W. E., Taylor, A. K., Riddle, J. E., Tran, H. X., & Hagerman, R. J. (1996). Fragile X syndrome in normal IQ males with learning and behavioral problems: Molecular-clinical correlations in males with an expanded FMR-1 mutation. Am J Med Genet, 64, 388–394.
Morton, J. E., Bundey, S., Webb, T. P., MacDonald, F., Rindl, P. M., & Bullock, S. (1997). Fragile X syndrome is less common than previously estimated. J Med Genet, 34, 1–5.
Morton, N. E., & Macpherson, J. N. (1992). Population genetics of the fragile X syndrome: Multiallelic model for the FMR1 locus. PNAS USA, 89, 4215–4217.
Murray, A., Ennis, S., MacSwiney, F., Webb, J., & Morton, N. E. (2000a). Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet, 8, 247–252.
Murray, A., Ennis, S., & Morton, N. (2000b). No evidence for parent of origin influencing premature ovarian failure in fragile X premutation carriers. Am J Hum Genet, 67, 253–254.
Murray, A., Youings, S., Dennis, N., Latsky, L., Linehan, P., McKechnie, N., et al. (1996). Population screening at the FRAXA and FRAXE loci: A molecular analysis of boys with learning difficulties and their mothers. Hum Mol Genet, 5, 727–735.
Musci, J., & Caughey, A. B. (2003). Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol, 189(Suppl), A197:S117.
National Society of Genetic Counselors (1995) National Society of Genetic Counselors, Position statement on prenatal and childhood testing for adult-onset disorders. Perspect Genet Couns, 17(3), 5.
Nolin, S. L., Brown, W. T., Glicksman, A., Houck, G. E., Gargano, A. D., Sullivan, A., et al. (2003). Expansion of the fragile X CGG repeat in females with premutations or intermediate alleles. Am J Hum Genet, 72, 454–464.
Nolin, S. L., Lewis, F. A., Ye, L. L., Houck, G. J., Glicksman, A. E., Limprasert, P., et al. (1996). Familial transmission of the FMR-1 CGG repeat. Am J Hum Genet, 59, 1252–1261.
Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., et al. (1991). Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science, 252, 1097–1102.
Palomaki, G. E. (1994). Population based prenatal screening for the fragile X syndrome. J Med Screen, 1, 65–72.
Pesso, R., Berkenstadt, M., Cuckle, H., Gak, E., Peleg, L., Frydman, M., et al. (2000). Screening for fragile X syndrome in women of reproductive age. Prenat Diagn, 20, 611–614.
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., et al. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell, 66, 817–822.
Platteau, P., Sermon, K., Seneca, S., Steirteghem, A. V., Devroey, P., & Liebaers, I. (2002). Preimplantation genetic diagnosis for fragile Xa syndrome: Difficult but not impossible. Hum Reprod, 17(11), 2807–2812.
Reiss, A. L., Kazazian, H. H., Krebs, C. M., McAughan, A., Boehm, C. D., Abrams, M. T., & Nelson, D. L. (1994). Frequency and stability of the fragile X premutation. Hum Mol Genet, 3, 393–398.
Resta, R. G., (Ed.) (2000). Psyche and helix, psychological aspects of genetic counseling. Essays by Seymour Kessler, PhD. New York: Wiley-Less.
Reyniers, E., Vits, I., De Boulle, K., Van Roy, B., Van Velzen, D., De Graaff, E., et al. (1993). The full mutation in the FMR1 gene of male fragile X patients is absent in their sperm. Nat Genet, 4, 143–146.
Rousseau, F., Heitz, D., Biancalana, V., Blumenfeld, S., Kretz, C., Boue, J., et al. (1991). Direct diagnosis by DNA analysis of the fragile X syndrome mental retardation. N Engl J Med, 325, 1673–1681.
Rousseau, F., Heitz, D., Tarleton, J., MacPherson, J., Malgran, H., Dahl, N., et al. (1994a). A multicenter study on genotype–phenotype correlation in the fragile X syndrome, using direct diagnosis with the probe STB 12.3: The first 2,253 cases. Am J Hum Genet, 55, 225–237.
Rousseau, F., Robb, L. J., Rouillard, P., & Der Kaloustian, V. M. (1994b). No mental retardation in a man with 40% abnormal methylation at the FMR-1 locus and transmission of sperm cells as premutation. Hum Mol Genet, 3, 927–930.
Rousseau, F., Rouillard, P., Khandjian, E. W., & Morgan, K. (1995). Prevalence of carriers of premutation-size alleles of the FRM1 gene and implications for the population genetics of the fragile X syndrome. Am J Hum Genet, 57, 1006–1018.
Ryynanen, M., Heinonen, S., Makkonen, M., Kajanoja, E., Mannermaa, A., & Pertti, K. (1999). Eur J Hum Genet, 7, 212–216.
Schwartz, C. E., Dean, J., Howard-Peebles, P. N., Bugge, M., Mikkelsen, M., Tommerup, N., et al. (1994). Obstetrical and gynecological complications in fragile X carriers: A multicenter study. Am J Med Genet, 51, 400–402.
Sermon, K., Seneca, S., Vanderfaeillie, A., Lissens, W., Joris, H., & Vandervorst, M. (1999). Preimplantation diagnosis for fragile X syndrome based on the detection of the non-expanded paternal and maternal CGG. Prenat Diagn, 19, 1223–1230.
Shapiro, L. R., Wilmot, P. L., Murphy, P. D., & Breg, W. R. (1988). Experience with multiple approaches to the prenatal diagnosis of the fragile X syndrome: Amniotic fluid, chorionic villi, fetal blood and molecular methods. Am J Med Genet, 30, 347–354.
Sherman, S. L. (2000). Premature ovarian failure in the fragile X syndrome. Am J Med Genet, 97, 189–194.
Sherman, S. L. (2002). Epidemiology. In R. Hagerman & P. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment and intervention (3rd Ed., pp. 136–168). Baltimore: The Johns Hopkins University Press.
Sherman, S. L., Meadows, K. L., & Ashley, A. E. (1996). Examination of factors that influence the expansion of the fragile X mutation. Am J Med Genet, 64, 256–260.
Sherman, S., Pletcher, B. A., & Driscoll, D. A. (in press). Fragile X syndrome: Diagnostic and carrier testing. Genetics in Medicine.
Shiloh, S., Berkenstadt, M., Meiran, N., Bat-Miriam- Katznelson, M., & Goldman, B. (1997). Mediating effects of perceived personal control in coping with a health threat: The case of genetic counseling. J Appl Soc Psychol, 27(13), 1146–1174.
Sills, E. S., Kirman, I., Thatcher, S. S., III, & Palermo, G. D. (1998). Sex-selection of human spermatozoa: Evolution of current techniques and applications. Arch Gynecol Obstet, 261(3), 109–115.
Skinner, D., Sparkman, K. L., & Bailey, D. B. (2003). Screening for fragile X syndrome: Parent attitudes and perspectives. Genet Med, 5, 378–384.
Smeets, H. J. M., Smits, A. P. T., Verheij, C. E., Theelen, J. P. G., Willemsen, R., Vande Burgt, I., et al. (1995). Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet, 4, 2103–2108.
Snow, K., Doud, L. K., Hagerman, R., Pergolizzi, R. G., Erster, S. H., & Thibodeau, S. N. (1993). Analysis of the CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet, 53, 1217–1228.
Sobesky, W. E., Pennington, B. F., Porter, D., Hull, C. E., & Hagerman, R. J. (1994). Emotional and neurocognitive deficits in fragile X. Am J Med Genet, 51, 378–385
Sullivan, A. K., Crawford, D. C., Scott, E. H., Leslie, M. L., & Sherman, S. L. (2002) Paternally transmitted FMR1 alleles are less stable than maternally transmitted alleles in the common and intermediate size range. Am J Hum Genet, 70, 1532–1544.
Sullivan, A. K., Marcus, M., Epstein, M. P., Allen, E. G., Anido, A. E., He, W., et al., (2005). Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod, 20, 402–412.
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., et al. (1992). DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet, 1, 397–400.
Sutherland, G. R. (1977). Fragile sites on human chromosome: Demonstration of their dependence on the type of tissue culture medium. Science, 197, 265–266.
Sybert, V. P. (2001). Turners syndrome. In S. B.Cassidy & J. E. Allanson (Eds.), Management of genetic syndromes (pp. 459–484). New York: Wiley-Liss.
Syrrou, M., Georgiou, I., Grigoriadou, M., Petersen, M., Kitsiou, S., Pagoulatos, G., et al. (1998). FRAXA and FRAXE prevalence in patients with nonspecific mental retardation in the Hellenic population. Genet Epidemiol, 15(1), 103–109.
Tarleton, J. C., & Saul, R. A. (1993). Molecular genetic advances in fragile X syndrome. J Pediatr, 122, 169–185.
Tassone, F., Hagerman, R. J., Taylor, A. K., Gane, L. W., Godfrey, T. E., et al. (2000). Elevated levels of FMR1 messenger RNA in carrier males: A new mechanism of involvement in the fragile X syndrome. Am J Hum Genet, 66, 6–15.
Taylor, A. K., Safianda, J. F., Fall, M. Z., Quince, C., Lange, K. A., Hull, C. E., et al. (1994). Molecular predicators of cognitive involvement in fragile X females. JAMA, 271, 507–514.
Terracciano, A., Pomponi, M. G., Marino, G. M., Chiurazzi, P., Rinaldi, M. M., Dobosz, M., et al. (2004). Expansion to full mutation of a FMR1 intermediate allele over two generations. Eur J Hum Genet, 12, 333–336.
Tiberio, G. (1994). MZ female twins discordant for X-linked diseases: A review. Acta Genet Med Gemellol, 43, 207–214.
Toledano-Alhadef, H., Basel-Vanagaite, L., Magal, N., Davidov, B., Ehrlich, S., Drasinover, V., et al. (2001). Fragile-X carrier screening and the prevalence of premutation and full- mutation carriers in Israel. Am J Hum Genet, 69, 352–360.
Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Campbell Grumet, S., et al. (2004). Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors. J Genet Couns, 13, 83–114.
Turner, G., Webb, T., Wake, S., & Robinson, H. (1996). The prevalence of the fragile X syndrome. Am J Med Genet, 64, 196–197.
U.S. General Accounting Office (2003). Newborn screening: Characteristics of state programs. Washington, DC. GAO-03–449. Available at http://www.gao.gov/atext/d03449.txt
U.S. Preventive Services Task Force. Chairman Harold C. Sox Jr. Guide to clinical preventive services (2nd Ed., Appendix A). U.S. Government Printing Office. Stock No. 017001005258 (1995).
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuho, D. P. A., Pizzuti, A., et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell, 65, 905–914.
Vianna-Morgante, A. M., & Costa, S. S. (2000). Premature ovarian failure is associated with maternally and paternally inherited premutation carriers in Brazilian families with fragile X syndrome. Am J Hum Genet, 67, 254–255.
Vits, L. M., De Boulle, K., Reyniers, E., Handig, I. Darby, J. K., Oostra, B., et al. (1994). Apparent regression of the CGG repeat in FMR1 to an allele of normal size. Hum Genet, 94, 523–526.
Weil, J. (2000). Psychosocial genetic counseling. New York: Oxford University Press.
Welt, C. K., Smith, P. C., & Taylor, A. E. (2004). Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab, 89, 4569–4574.
Willemsen, R., Bontekoe, C. J., Severijnen, L. A., & Oostra, B. A. (2002). Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet, 110(6), 601–605.
Williams, J. K., Schutte, D. L., Evers, C., & Holkup, P. A. (2000). Redefinition: Coping with normal results from predictive gene testing for neurodegenerative disorders. Res Nurs Health, 23, 260–269.
Wohrle, D., Hennig, I., Vogel, W., & Steinbach, P. (1993). Mitotic stability of fragile X mutations in differentiated cells indicates early post-conceptional trinucleotide repeat expansion. Nat Genet, 4, 140–142.
Wohrle, D., Kotzot, D., Hirst, M. C., Manca, A., Korn, B., Schmidt, A., et al. (1992). A microdeletion of less than 250 kb, including the proximal part of the FMR-1 gene and the fragile X site, in a male with the clinical phenotype of fragile X syndrome. Am J Hum Genet, 51, 299–306.
Yu, S., Pritchard, M., Kremer, E., Lynch, M., Nancarrow, J., Baker, E., et al. (1991). Fragile X genotype characterized by an unstable region of DNA. Science, 252, 1179–1181.
Zeesman, S., Zwaigenbaum, L., Whelan, D. T., Hagerman, R. J., Tassone, F., & Taylor, S. A. (2004). Paternal transmission of fragile X syndrome. Am J Med Genet, 129A(2), 184–189.
Zhong, N., Ju, W., Pietrofesa, J., Wang, D., Dobkin, C., & Brown, W. T. (1996). Fragile X “gray zone” alleles: AGG patterns, expansion risks and associated haplotypes. Am J Med Genet, 64, 26.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McConkie-Rosell, A., Finucane, B., Cronister, A. et al. Genetic Counseling for Fragile X Syndrome: Updated Recommendations of the National Society of Genetic Counselors. J Genet Counsel 14, 249–270 (2005). https://doi.org/10.1007/s10897-005-4802-x
Issue Date:
DOI: https://doi.org/10.1007/s10897-005-4802-x